The global market for Liposomal Drug Delivery System was valued at US$ 4361 million in the year 2024 and is projected to reach a revised size of US$ 9077 million by 2031, growing at a CAGR of 11.2% during the forecast period.
A liposomal drug delivery system refers to a method of delivering therapeutic agents, such as drugs or genetic material, using liposomes. Liposomes are microscopic vesicles composed of lipid bilayers, mimicking the structure of cell membranes. These vesicles can encapsulate drugs, protecting them from degradation and improving their delivery to specific target tissues or cells in the body.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Liposomal Drug Delivery System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal Drug Delivery System.
The Liposomal Drug Delivery System market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Liposomal Drug Delivery System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liposomal Drug Delivery System companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson & Johnson Services, Inc. (U.S.)
Gilead Sciences Inc. (U.S.)
Sun Pharmaceutical Industries Ltd. (India)
Novartis AG (Switzerland)
Teva Pharmaceutical Industries Ltd (Israel)
Janssen Pharmaceuticals Inc. (Belgium)
CELSION corporation (U.S.）
Abbott (U.S.)
Ipsen Pharma (France)
Spectrum Pharmaceuticals, Inc. (U.S.)
Takeda Pharmaceutical Company Limited. (Japan)
Segment by Type
Liposomal Doxorubicin
Liposomal Paclitaxel
Liposomal Amphotericin B
Others
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liposomal Drug Delivery System company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Liposomal Drug Delivery System Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Liposomal Doxorubicin
1.2.3 Liposomal Paclitaxel
1.2.4 Liposomal Amphotericin B
1.2.5 Others
1.3 Market by Application
1.3.1 Global Liposomal Drug Delivery System Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liposomal Drug Delivery System Market Perspective (2020-2031)
2.2 Global Liposomal Drug Delivery System Growth Trends by Region
2.2.1 Global Liposomal Drug Delivery System Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Liposomal Drug Delivery System Historic Market Size by Region (2020-2025)
2.2.3 Liposomal Drug Delivery System Forecasted Market Size by Region (2026-2031)
2.3 Liposomal Drug Delivery System Market Dynamics
2.3.1 Liposomal Drug Delivery System Industry Trends
2.3.2 Liposomal Drug Delivery System Market Drivers
2.3.3 Liposomal Drug Delivery System Market Challenges
2.3.4 Liposomal Drug Delivery System Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liposomal Drug Delivery System Players by Revenue
3.1.1 Global Top Liposomal Drug Delivery System Players by Revenue (2020-2025)
3.1.2 Global Liposomal Drug Delivery System Revenue Market Share by Players (2020-2025)
3.2 Global Liposomal Drug Delivery System Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Liposomal Drug Delivery System Revenue
3.4 Global Liposomal Drug Delivery System Market Concentration Ratio
3.4.1 Global Liposomal Drug Delivery System Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liposomal Drug Delivery System Revenue in 2024
3.5 Global Key Players of Liposomal Drug Delivery System Head office and Area Served
3.6 Global Key Players of Liposomal Drug Delivery System, Product and Application
3.7 Global Key Players of Liposomal Drug Delivery System, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Liposomal Drug Delivery System Breakdown Data by Type
4.1 Global Liposomal Drug Delivery System Historic Market Size by Type (2020-2025)
4.2 Global Liposomal Drug Delivery System Forecasted Market Size by Type (2026-2031)
5 Liposomal Drug Delivery System Breakdown Data by Application
5.1 Global Liposomal Drug Delivery System Historic Market Size by Application (2020-2025)
5.2 Global Liposomal Drug Delivery System Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Liposomal Drug Delivery System Market Size (2020-2031)
6.2 North America Liposomal Drug Delivery System Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Liposomal Drug Delivery System Market Size by Country (2020-2025)
6.4 North America Liposomal Drug Delivery System Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liposomal Drug Delivery System Market Size (2020-2031)
7.2 Europe Liposomal Drug Delivery System Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Liposomal Drug Delivery System Market Size by Country (2020-2025)
7.4 Europe Liposomal Drug Delivery System Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liposomal Drug Delivery System Market Size (2020-2031)
8.2 Asia-Pacific Liposomal Drug Delivery System Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Liposomal Drug Delivery System Market Size by Region (2020-2025)
8.4 Asia-Pacific Liposomal Drug Delivery System Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liposomal Drug Delivery System Market Size (2020-2031)
9.2 Latin America Liposomal Drug Delivery System Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Liposomal Drug Delivery System Market Size by Country (2020-2025)
9.4 Latin America Liposomal Drug Delivery System Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liposomal Drug Delivery System Market Size (2020-2031)
10.2 Middle East & Africa Liposomal Drug Delivery System Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Liposomal Drug Delivery System Market Size by Country (2020-2025)
10.4 Middle East & Africa Liposomal Drug Delivery System Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson Services, Inc. (U.S.)
11.1.1 Johnson & Johnson Services, Inc. (U.S.) Company Details
11.1.2 Johnson & Johnson Services, Inc. (U.S.) Business Overview
11.1.3 Johnson & Johnson Services, Inc. (U.S.) Liposomal Drug Delivery System Introduction
11.1.4 Johnson & Johnson Services, Inc. (U.S.) Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.1.5 Johnson & Johnson Services, Inc. (U.S.) Recent Development
11.2 Gilead Sciences Inc. (U.S.)
11.2.1 Gilead Sciences Inc. (U.S.) Company Details
11.2.2 Gilead Sciences Inc. (U.S.) Business Overview
11.2.3 Gilead Sciences Inc. (U.S.) Liposomal Drug Delivery System Introduction
11.2.4 Gilead Sciences Inc. (U.S.) Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.2.5 Gilead Sciences Inc. (U.S.) Recent Development
11.3 Sun Pharmaceutical Industries Ltd. (India)
11.3.1 Sun Pharmaceutical Industries Ltd. (India) Company Details
11.3.2 Sun Pharmaceutical Industries Ltd. (India) Business Overview
11.3.3 Sun Pharmaceutical Industries Ltd. (India) Liposomal Drug Delivery System Introduction
11.3.4 Sun Pharmaceutical Industries Ltd. (India) Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.3.5 Sun Pharmaceutical Industries Ltd. (India) Recent Development
11.4 Novartis AG (Switzerland)
11.4.1 Novartis AG (Switzerland) Company Details
11.4.2 Novartis AG (Switzerland) Business Overview
11.4.3 Novartis AG (Switzerland) Liposomal Drug Delivery System Introduction
11.4.4 Novartis AG (Switzerland) Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.4.5 Novartis AG (Switzerland) Recent Development
11.5 Teva Pharmaceutical Industries Ltd (Israel)
11.5.1 Teva Pharmaceutical Industries Ltd (Israel) Company Details
11.5.2 Teva Pharmaceutical Industries Ltd (Israel) Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd (Israel) Liposomal Drug Delivery System Introduction
11.5.4 Teva Pharmaceutical Industries Ltd (Israel) Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.5.5 Teva Pharmaceutical Industries Ltd (Israel) Recent Development
11.6 Janssen Pharmaceuticals Inc. (Belgium)
11.6.1 Janssen Pharmaceuticals Inc. (Belgium) Company Details
11.6.2 Janssen Pharmaceuticals Inc. (Belgium) Business Overview
11.6.3 Janssen Pharmaceuticals Inc. (Belgium) Liposomal Drug Delivery System Introduction
11.6.4 Janssen Pharmaceuticals Inc. (Belgium) Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.6.5 Janssen Pharmaceuticals Inc. (Belgium) Recent Development
11.7 CELSION corporation (U.S.）
11.7.1 CELSION corporation (U.S.） Company Details
11.7.2 CELSION corporation (U.S.） Business Overview
11.7.3 CELSION corporation (U.S.） Liposomal Drug Delivery System Introduction
11.7.4 CELSION corporation (U.S.） Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.7.5 CELSION corporation (U.S.） Recent Development
11.8 Abbott (U.S.)
11.8.1 Abbott (U.S.) Company Details
11.8.2 Abbott (U.S.) Business Overview
11.8.3 Abbott (U.S.) Liposomal Drug Delivery System Introduction
11.8.4 Abbott (U.S.) Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.8.5 Abbott (U.S.) Recent Development
11.9 Ipsen Pharma (France)
11.9.1 Ipsen Pharma (France) Company Details
11.9.2 Ipsen Pharma (France) Business Overview
11.9.3 Ipsen Pharma (France) Liposomal Drug Delivery System Introduction
11.9.4 Ipsen Pharma (France) Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.9.5 Ipsen Pharma (France) Recent Development
11.10 Spectrum Pharmaceuticals, Inc. (U.S.)
11.10.1 Spectrum Pharmaceuticals, Inc. (U.S.) Company Details
11.10.2 Spectrum Pharmaceuticals, Inc. (U.S.) Business Overview
11.10.3 Spectrum Pharmaceuticals, Inc. (U.S.) Liposomal Drug Delivery System Introduction
11.10.4 Spectrum Pharmaceuticals, Inc. (U.S.) Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.10.5 Spectrum Pharmaceuticals, Inc. (U.S.) Recent Development
11.11 Takeda Pharmaceutical Company Limited. (Japan)
11.11.1 Takeda Pharmaceutical Company Limited. (Japan) Company Details
11.11.2 Takeda Pharmaceutical Company Limited. (Japan) Business Overview
11.11.3 Takeda Pharmaceutical Company Limited. (Japan) Liposomal Drug Delivery System Introduction
11.11.4 Takeda Pharmaceutical Company Limited. (Japan) Revenue in Liposomal Drug Delivery System Business (2020-2025)
11.11.5 Takeda Pharmaceutical Company Limited. (Japan) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Johnson & Johnson Services, Inc. (U.S.)
Gilead Sciences Inc. (U.S.)
Sun Pharmaceutical Industries Ltd. (India)
Novartis AG (Switzerland)
Teva Pharmaceutical Industries Ltd (Israel)
Janssen Pharmaceuticals Inc. (Belgium)
CELSION corporation (U.S.）
Abbott (U.S.)
Ipsen Pharma (France)
Spectrum Pharmaceuticals, Inc. (U.S.)
Takeda Pharmaceutical Company Limited. (Japan)
Ìý
Ìý
*If Applicable.
